- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05201027
Study to Optimize the IOL Constant of a New Multifocal Intraocular Lens (HECATE A)
August 19, 2022 updated by: Carl Zeiss Meditec AG
A Prospective, Non-comparative, Multicenter Trial to Optimize the IOL Constant of a New Multifocal IOL
Prospective, non-comparative, multicenter study on medical device with 6 months follow-up.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
52
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
San Salvador, El Salvador
- Clinica Quesada
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult patient of any gender;
- Patient with clinically significant bilateral age-related cataracts with planned phacoemulsification cataract extraction and suitable for implantation of a posterior chamber trifocal intraocular lens as determined by investigator's medical judgement;
- Projected postoperative corrected distance visual acuity (CDVA) better than 0.2 LogMAR as determined by investigator's medical judgement;
- Preoperative keratometric (corneal) astigmatism ≤1.5 D;
- Clear intraocular media other than cataract;
- Requiring an IOL power within the available range of the investigational IOL (15.0 to +27.0 D, in 0.5 D increments);
- Patient agrees to have surgery of the second eye performed between 1 day and 10 days after the surgery of the first eye.
- Given written informed consent by patient;
- Patient willing and able to comply with examination procedures and schedule for follow-up visits;
Exclusion Criteria:
- Presence of uncontrolled systemic disease that could increase the operative risk or confound the outcome including but not limited to diabetes mellitus, active cancer treatment, mental illness, dementia, immunocompromised, connective tissue disease, clinically significant atopic disease, etc.;
- Ocular condition that may predispose patient to future complications, per investigator's medical judgement, including but not limited to severe dry eye, anterior segment pathology, glaucoma (uncontrolled despite intake of medication), macular degeneration;
- Clinically significant corneal abnormalities, including corneal dystrophy (epithelial, stromal or endothelial dystrophy), irregularity, inflammation or oedema as per Investigator's medical judgement; conditions including but not limited to keratitis, keratoconjunctivitis, kerato uveitis, keratopathy, keratectasia;
- Previous intraocular or corneal/refractive surgery that might confound the outcome of the investigation or increase the risk to the patient (including corneal transplants, removal of pterygium etc.);
- Use of and foreseeable use of systemic medications that may confound the outcome or increase the risk to the patient per investigator's medical judgement (e.g., steroids, Tamsulosin Hydrochloride or other medications including anticholinergics or alpha-adrenergic blocking agents with similar side effects [e.g. small pupil/floppy iris syndrome], anti-metabolites, etc.);
- Patients with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders, optic nerve atrophy etc.) or any other pathologies of the eye that are predicted to cause future acuity loss to 0.2 LogMAR (CDVA) or worse;
- Patients with conditions that increase the risk of zonular rupture during cataract extraction procedure that may affect the postoperative centration or tilt of the lens;
- Patients with previous refractive surgery procedures, including but not limited to LASIK, limbal relaxing incision;
- Planned concomitant ocular procedure during cataract surgery or within the next 6 months (e.g. glaucoma surgery including implantation of MIGS, astigmatic correction surgery, penetrating keratoplasty, laser-assisted in situ keratomileusis);
- Patients who are expected to require retinal laser treatment within the next 6 months per investigator's medical judgement;
- Amblyopia;
- Rubella, congenital, traumatic or complicated cataracts;
- History of or current anterior or posterior segment inflammation, including but not limited to iritis or uveitis;
- Microphthalmos or macrophthalmos;
- Iris defects (e.g. aniridia);
- Optic nerve atrophy;
- Pseudoexfoliation;
- Keratoconus or irregular astigmatism;
- Inability to measure keratometry or biometry (including but not limited to cataract density, patient unable to focus for longer time etc.);
- Pathologic miosis;
- Pregnant, lactating during the course of the investigation, or another condition with associated fluctuation of hormones that could lead to refractive changes;
- Patient whose freedom is impaired by administrative or legal order;
- Concurrent participation in another drug or device investigation that could confound the outcome of this investigation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: trifocal intraocular lens
Implantation of new trifocal intraocular lens
|
cataract extraction and implantation of a posterior chamber trifocal intraocular lens
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Optimization of the IOL constant
Time Frame: 6 months
|
Optimization of the calculated IOL constant with regression analysis by utilizing the following data measured during the study: Corneal radii, axial length, anterior chamber depth, IOL power, target refraction, manifest refraction and refraction distance
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 28, 2022
Primary Completion (Actual)
July 27, 2022
Study Completion (Actual)
July 27, 2022
Study Registration Dates
First Submitted
January 6, 2022
First Submitted That Met QC Criteria
January 20, 2022
First Posted (Actual)
January 21, 2022
Study Record Updates
Last Update Posted (Actual)
August 22, 2022
Last Update Submitted That Met QC Criteria
August 19, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AT ELANA 841P-BER-301-19
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cataract Senile
-
Vienna Institute for Research in Ocular SurgeryRecruiting
-
Taipei Nobel Eye ClinicCompletedCataract SenileTaiwan
-
Wendell ScottJohnson & Johnson Surgical Vision, Inc.CompletedCataract SenileUnited States
-
Carl Zeiss Meditec AGCompletedCataract SenileRomania
-
Carl Zeiss Meditec AGCompleted
-
Johannes Kepler University of LinzCompleted
-
Vienna Institute for Research in Ocular SurgeryCompleted
-
Qinghai UniversityUnknown
-
Johannes Kepler University of LinzWithdrawn
-
AST Products, Inc.Completed
Clinical Trials on trifocal intraocular lens
-
Carl Zeiss Meditec AGActive, not recruitingCataract SenileCzechia, Germany, Slovakia
-
Eye & ENT Hospital of Fudan UniversityActive, not recruiting
-
Carl Zeiss Meditec AGCompleted
-
Parkhurst NuVision Clinical Research LLCAlcon ResearchRecruitingRefractive Errors | CataractUnited States
-
Alexandria UniversityCompletedRefractive ErrorsEgypt
-
Beaver-Visitec International, Inc.Completed
-
Johnson & Johnson Surgical Vision, Inc.CompletedRefractive Error | CataractPhilippines, New Zealand, Spain
-
Weill Medical College of Cornell UniversityAlcon ResearchCompleted
-
Increase-TechMinisterio de Economía y Competitividad, Spain; University of Alicante; Instituto...CompletedVisual Acuity Reduced Transiently | Visual Disturbances and BlindnessSpain